Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases. A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement. This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events. Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more

Produk Detail:

  • Author : Giuseppe Tridente
  • Publisher : Academic Press
  • Pages : 736 pages
  • ISBN : 0128094451
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKAdverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors
  • Author : Giuseppe Tridente
  • Publisher : Academic Press
  • Release : 08 May 2017
GET THIS BOOKAdverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases. A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s)

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 21 November 2018
GET THIS BOOKProtein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic,

Side Effects of Drugs Annual

Side Effects of Drugs Annual
  • Author : Anonim
  • Publisher : Elsevier
  • Release : 19 October 2017
GET THIS BOOKSide Effects of Drugs Annual

Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 39 presents the latest on a variety of topics, with new chapters in this volume covering Central nervous system stimulants and drugs that suppress appetite, Antidepressant drugs, Lithium, Drugs of abuse, Hypnotics and sedatives, Antipsychotic Drugs, Antiepileptic Drugs, Opioid analgesics and narcotic antagonists, Anti-inflammatory and antipyretic analgesics and drugs used in gout, General anesthetics and therapeutic gases, Local anesthetics, Neuromuscular blocking agents and skeletal

FDA's Drug Review Process and the Package Label

FDA's Drug Review Process and the Package Label
  • Author : Tom Brody
  • Publisher : Academic Press
  • Release : 13 December 2017
GET THIS BOOKFDA's Drug Review Process and the Package Label

FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data

Anti-fibrotic Drug Discovery

Anti-fibrotic Drug Discovery
  • Author : Jehrod Brenneman,Malliga R Iyer
  • Publisher : Royal Society of Chemistry
  • Release : 17 February 2020
GET THIS BOOKAnti-fibrotic Drug Discovery

Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book

Adverse Events with Biomedicines

Adverse Events with Biomedicines
  • Author : Giuseppe Tridente
  • Publisher : Springer Science & Business Media
  • Release : 09 December 2013
GET THIS BOOKAdverse Events with Biomedicines

This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those “biomedicines” – monoclonal antibodies, fusion proteins, and cytokines – that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms

Immunotherapy

Immunotherapy
  • Author : Aung Naing,Joud Hajjar
  • Publisher : Springer Nature
  • Release : 16 April 2020
GET THIS BOOKImmunotherapy

Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care

Chemical Proteomics

Chemical Proteomics
  • Author : Gerard Drewes,Marcus Bantscheff
  • Publisher : Humana Press
  • Release : 17 November 2011
GET THIS BOOKChemical Proteomics

The multidisciplinary science of chemical proteomics studies how small molecules of synthetic or natural origin bind to proteins and modulate their function. In Chemical Proteomics: Methods and Protocols, expert researchers in the field provide key techniques to investigate chemical proteomics focusing on analytical strategies, how probes are generated, techniques for the discovery of small molecule targets and the probing of target function, and small molecule ligand and drug discovery. Written in the highly successful Methods in Molecular BiologyTM series format,

Hospital-Based Dermatopathology

Hospital-Based Dermatopathology
  • Author : Mai P. Hoang,Maria Angelica Selim
  • Publisher : Springer Nature
  • Release : 28 February 2020
GET THIS BOOKHospital-Based Dermatopathology

This book provides a concise reference of the histologic and clinical findings of dermatologic conditions encountered in the inpatient setting. The text is divided into twenty chapters. Histopathologic images and corresponding clinical photographs facilitate clinical pathologic correlation of the conditions discussed in each chapter. Bulleted summaries for quick easy-to-read reference and diagnostic pearls are provided for each of the discussed entities. Each chapter ends with several case studies in which clinical presentation, histologic interpretation and work-up of these challenging scenarios

Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma
  • Author : Antonio Giordano,Renato Franco
  • Publisher : Academic Press
  • Release : 21 February 2019
GET THIS BOOKMalignant Pleural Mesothelioma

Malignant Pleural Mesothelioma: A Guide for Clinicians is a practical book developed to assist clinicians, pathologist and molecular biologist in the management of malignant pleural mesothelioma (MPM). MPM represents a challenge in terms of diagnosis, staging and treatment, and to date, the optimal management of MPM patients has not yet been clearly defined – and this book is intended to be an efficient tool for these cases. The book encompasses topics such as epidemiology and surveillance evidence, multimodality imaging assessment of

Uncommon Gynecologic Cancers

Uncommon Gynecologic Cancers
  • Author : Marcela del Carmen,John O. Schorge,Robert H. Young
  • Publisher : John Wiley & Sons
  • Release : 11 November 2014
GET THIS BOOKUncommon Gynecologic Cancers

Rare gynecological cancers kill all too commonly Gynecological cancer is a frightening prospect for women. It isterrifying also for physicians who need, but often can’tfind, guidance on how to investigate and appropriately treat thetumors. Rare cancers provide greater challenges as information canbe harder to find and more difficult to verify. Rare Gynecologic Cancers: Diagnosis and Management bringstogether all you need to know on these life-threatening diseases.Straightforward summaries of pathophysiologic processes lead to theinvestigations that will improve your diagnostic

Small Molecules in Oncology

Small Molecules in Oncology
  • Author : Uwe M. Martens
  • Publisher : Springer Science & Business Media
  • Release : 14 January 2010
GET THIS BOOKSmall Molecules in Oncology

Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of

Small Molecules in Hematology

Small Molecules in Hematology
  • Author : Uwe M. Martens
  • Publisher : Springer
  • Release : 01 August 2018
GET THIS BOOKSmall Molecules in Hematology

This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms